• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

    9/11/23 7:00:00 AM ET
    $ELDN
    $URGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELDN alert in real time by email

    IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023.

    "I am pleased to welcome Jim to our Board and look forward to working with him," said David-Alexandre C. Gros, M.D., Chief Executive Officer. "Jim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatment option to the growing number of patients undergoing kidney transplantation. His experience as a leader in the biopharmaceutical industry will be invaluable in this next phase of Eledon's trajectory."

    As Chief Executive Officer and Director of Urovant Sciences, Mr. Robinson guided the company through FDA approval of its first drug, a successful product launch, and its acquisition and "take-private" transaction by Sumitomo Dainippon Pharma. Prior to Urovant, he was President and Chief Operating Officer of Paragon Biosciences. Before his time at Paragon, Mr. Robinson served as President and COO of Alkermes, leading operations that generated more than $1 billion in annual revenue. Prior to Alkermes, Mr. Robinson spent over 12 years at Astellas Pharma, one of the leaders in the field of solid organ transplant, where he served as President of the Americas and was responsible for approximately $4 billion in revenue generation.

    Mr. Robinson currently serves on the Board of Directors of UroGen Pharma (NASDAQ:URGN). He previously served on the Board of Directors for Neos Therapeutics and for AGTC before the company was sold to Syncona. Mr. Robinson also previously served on the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he served as Chairman of PhRMA's State Committee. He earned a Bachelor of Science in marketing from DePaul University.

    "I am inspired by Eledon's mission to address a therapeutic area with thousands of patients in need of a better option to protect their transplanted organs," said Mr. Robinson. "Backed by strong scientific rationale and promising clinical results to date, tegoprubart has the potential to change the outlook for patients with transplanted kidneys and help alleviate shortages of available kidneys by preserving the kidneys in transplant patients. I look forward to leveraging my background and experience while working closely with the Eledon management team to continue advancing tegoprubart through the clinic."

    About Eledon Pharmaceuticals and tegoprubart

    Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company's website at www.eledon.com.

    Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about planned clinical trials and the Company's other future expectations, plans and prospects, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "predicts," "projects," "targets," "looks forward," "could," "may," and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sides, as well as patient enrollment; risks relating to costs of clinical trials and the sufficiency of the company's capital resources to fund planned clinical trials; and risks associated with the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company's actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Contact:

    Stephen Jasper

    Gilmartin Group

    (858) 525 2047

    [email protected]

    Media Contact:

    Jenna Urban

    Berry & Company Public Relations

    (212) 253 8881

    [email protected]

    Source: Eledon Pharmaceuticals



    Primary Logo

    Get the next $ELDN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELDN
    $URGN

    CompanyDatePrice TargetRatingAnalyst
    Eledon Pharmaceuticals Inc.
    $ELDN
    6/18/2025$9.00Buy
    H.C. Wainwright
    UroGen Pharma Ltd.
    $URGN
    6/16/2025$50.00Neutral → Buy
    H.C. Wainwright
    UroGen Pharma Ltd.
    $URGN
    5/22/2025Buy → Neutral
    H.C. Wainwright
    UroGen Pharma Ltd.
    $URGN
    4/16/2025$23.00Sector Outperform
    Scotiabank
    UroGen Pharma Ltd.
    $URGN
    2/19/2025$31.00Buy
    Ladenburg Thalmann
    Eledon Pharmaceuticals Inc.
    $ELDN
    1/28/2025$9.00Buy
    Guggenheim
    UroGen Pharma Ltd.
    $URGN
    8/22/2024$40.00Buy
    Guggenheim
    UroGen Pharma Ltd.
    $URGN
    2/8/2023$35.00 → $10.00Buy → Hold
    Jefferies
    More analyst ratings

    $ELDN
    $URGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Barrett Elizabeth A.

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      7/30/25 4:08:22 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • General Counsel Smith Jason Drew sold $143,971 worth of Ordinary Shares (7,522 units at $19.14) and converted options into 16,500 units of Ordinary Shares, increasing direct ownership by 28% to 41,492 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      7/30/25 4:03:45 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Schoenberg Mark converted options into 10,000 units of Ordinary Shares and sold $98,552 worth of Ordinary Shares (5,149 units at $19.14), increasing direct ownership by 3% to 158,229 units (SEC Form 4)

      4 - UroGen Pharma Ltd. (0001668243) (Issuer)

      7/30/25 4:02:05 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    $URGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

      IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conferen

      7/30/25 4:05:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

      Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay wil

      7/29/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

      PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results from a Phase 3b study evaluating the feasibility of administering ZUSDURI™ (mitomycin) for intravesical solution (formerly known as UGN-102) in the home setting. The study, titled "Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: A Single-Arm, Open-Label, Phase 3b Trial," demonstrated that trained home health professionals (HHPs) can safely

      7/28/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    $URGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Eledon Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $9.00

      6/18/25 7:57:38 AM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded UroGen Pharma from Neutral to Buy and set a new price target of $50.00

      6/16/25 7:44:13 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma downgraded by H.C. Wainwright

      H.C. Wainwright downgraded UroGen Pharma from Buy to Neutral

      5/22/25 8:22:21 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    $URGN
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Eledon Pharmaceuticals Inc.

      SCHEDULE 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)

      7/29/25 1:13:10 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by UroGen Pharma Ltd.

      DEF 14A - UroGen Pharma Ltd. (0001668243) (Filer)

      7/15/25 4:56:18 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by UroGen Pharma Ltd.

      8-K - UroGen Pharma Ltd. (0001668243) (Filer)

      7/3/25 4:16:10 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    $URGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bvf Partners L P/Il bought 1,927,937 shares (SEC Form 4)

      4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)

      5/13/24 5:04:15 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    $URGN
    Leadership Updates

    Live Leadership Updates

    See more
    • UroGen Appoints Chris Degnan as Chief Financial Officer

      Mr. Degnan has extensive experience in financial strategy, investor relations, SEC reporting, accounting and compliance UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that Chris Degnan has been appointed Chief Financial Officer. Mr. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. "Under Don's financial stewardship, we have strengthened our financial position and achieved significant milestones, which include multiple capital raises and investing in the potential commercial launch of UGN-102 for low-grade intermediate-risk non-musc

      10/9/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma Appoints David Lin as New Chief Commercial Officer

      UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced that David Lin will join UroGen as its Chief Commercial Officer and member of the Executive Leadership Team. In this role, David will be spearheading UroGen's commercial strategy, including preparation for the potential launch of our lead pipeline candidate UGN-102, if approved, and driving the continued growth and commercialization of JELMYTO® (mitomycin) for pyelocalyceal solution. David Lin brings to UroGen a wealth of experience garnered from a distinguished career in the pharmaceutical industry. Prior to joining U

      6/3/24 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • NorthStar Appoints Peter Pfreundschuh to Board of Managers

      NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, today announced the appointment of Peter (Pete) Pfreundschuh to its Board of Managers, effective April 1, 2024. Following this appointment, the Board will comprise of 9 directors, 6 of whom are non-executive. "We are pleased to welcome Pete to the NorthStar Board," said Stephen Merrick, Executive Chairman of NorthStar. "Pete has deep experience in the pharmaceutical and biotechnology industry, with extensive knowledge in corporate finance, business

      4/15/24 9:00:00 AM ET
      $FREQ
      $URGN
      $VYGR
      $IMMU
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $ELDN
    $URGN
    Financials

    Live finance-specific insights

    See more
    • Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

      IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025. To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conferen

      7/30/25 4:05:00 PM ET
      $ELDN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

      Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. A live public webcast of the earnings conference call can be accessed on UroGen's Investor Relations website. Following the live webcast, a replay wil

      7/29/25 8:00:00 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

      ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders maintained complete response at 12 months after the 3-month visit (DOR). Manageable safety profile characterized primarily by mild to moderate lower urinary tract symptoms. An estimated 59,000 LG-IR-NMIBC patients in the U.S. recur each year and face repeat surgeries. Conference call and webcast to be held on June 13, 2025, at 8:30 AM ET UroGen Pharma Ltd. (NASDAQ:URGN), a biotech com

      6/12/25 1:28:00 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ELDN
    $URGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by UroGen Pharma Ltd.

      SC 13D/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/18/24 6:16:04 AM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 7:46:37 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by UroGen Pharma Ltd.

      SC 13G/A - UroGen Pharma Ltd. (0001668243) (Subject)

      11/14/24 5:46:12 PM ET
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care